Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Features

Features
Emerging Drug Discovery Targets: 21st Oct

21 Oct 03

Emerging Drug Discovery Targets" provides a twice monthly summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition of features data highlighting technology for improved wound healing; a new candidate asthma treatment; a novel approach to diabetes and combination therapy offering improved radiotherapy responsiveness. As usual we also provide updates on industrial advances and licensing opportunities.
LeadDiscovery

Cx43 as a target for improved wound healing

15 Oct 03

Worldwide, 95 million people suffer from wounds that result in tissue loss. Wound healing problems extend hospital stays, especially in the elderly, resulting in an additional $1.5 billion in healthcare costs in the US alone. LeadDiscovery’s current target of the month focuses on connexin43, blocking of which produces a dramatic improvement in wound healing. In this feature we also describe how antisense technology has been applied to develop a licensing opportunity in this area
LeadDiscovery

Pharma NewsBytes - Oct 13

15 Oct 03

Pharma NewsBytes is LeadDiscovery’s selection of recent press releases for the drug development. Currently featured news items include those announcing promising clinical data for Antigenics' pancreatic cancer Oncophage vaccine; FDA backing for Forest's new Alzheimer's disease drug, Memantine; early figures on the sale of AstraZeneca's anti-cholerstremic drug Crestor; and FDA approval of Pfizer's potential blockbuster, Inspira for the treatment of congestive heart failure
LeadDiscovery

Puppet, partner or parasite?

14 Oct 03

The role of clinical recruitment agencies may be perceived in different ways, but there is a clear demand for expertise delivered in an open and transparent fashion. Agencies must therefore work in partnership, not in parallel, with customers.
Sylvia Kempsell

Emerging Drug Discovery Targets

01 Oct 03

"Emerging Drug Discovery Targets" summarizes the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. This edition explores recent advances in the use of siRNA technology in oncology, new molecular targets for the treatment of diabetes and advances in the development of GSK-3 inhibitors. Recent preselected press releases are also highlighted and as usual new licensing opportunities, breaking publications and new industry reports are all identified.
LeadDiscovery

Development of Glycogen synthase kinase-3 (GSK-3) inhibitors by GlaxoSmithKline and by Johnson & Johnson (Target of the Month, TherapeuticAdvances, September, 2003)

25 Sep 03

Proof of concept studies have accumulated supporting the targeting of glycogen synthase kinase-3 (GSK-3) for the treatment of diabetes and CNS conditions. Now inhibitors are emerging as therapeutic candidates
LeadDiscovery

Ghrelin: Pharmaceutical & Therapeutic Opportunities for the Treatment of Obesity

23 Sep 03

"Ghrelin: Pharmaceutical & Therapeutic Opportunities for the Treatment of Obesity" represents a cutting edge analysis of why and how ghrelin should be targeted for the identification of new therapies for obesity
LeadDiscovery

The Outlook for Gene Therapy

26 Aug 03

As it aims to correct the underlying genetic defects in human disease rather than just focusing on symptoms, gene therapy offers the potential for actual cures. However, several technical and safety issues have hampered progress.
Dr Faiz Kermani

The Kv1.3 potassium channel as a target for multip

05 Aug 03

Research towards the development of ion channel modulators is booming. One exciting target is the Kv1.3 voltage activated potassium channel. Expressed by human T lymphocytes Kv1.3 is involved in proliferation and cytokine secretion. Animal studies have established Kv1.3 as a target for the unmet multiple sclerosis (MS) market. Further key proof of concept data has now emerged demonstrating the selective expression of this channel in myelin-reactive effector memory T cells from MS patients
LeadDiscovery

Pharma NewsBytes (August, 2003)

05 Aug 03

Pharma NewsBytes is LeadDiscovery's summary of news items released from the pharmaceutical and biotech sector over the previous two weeks. This week we feature the FDA's backing of the statin, Crestor; a new agreement based on the development of HDAC inhibitors which could leed to imporved cancer therapeutics; a novel and highly promising approach to metabolic disease announced by Roche; emerging clinical data on what appears to be an effective treatment of primary liver cancer and more.....
LeadDiscovery

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.